Skip to main content

Table 5 Univariate/multivariate analyses of factors associated with prognosis in the p-DCS group

From: Potential of extravasated platelet aggregation as a surrogate marker for overall survival in patients with advanced gastric cancer treated with preoperative docetaxel, cisplatin and S-1: a retrospective observational study

 

Univariate analysis

Multivariate analysis

Variable

No. of patients

HR

95% CI

P value

HR

95% CI

P value

Age (years)

≥70

15

1.470

(0.607–3.560)

0.393

   

<70

24

Gender

Male

32

0.409

(0.156–1.075)

0.070

0.281

(0.093–0.846)

0.024

Female

7

ECOG performance status

≥1

2

0.894

(0.119–6.698)

0.913

   

0

37

Borrmann macroscopic type

Non-type 4

38

0.452

(0.059–3.439)

0.443

   

Type 4

1

Differentiation

Diffuse

18

0.758

(0.310–1.854)

0.543

   

Intestinal

21

PAN metastasis

(+)

16

1.869

(0.539–4.854)

0.201

   

(−)

23

Hepatic metastasis

(+)

9

2.508

(0.993–6.333)

0.052

1.718

(0.530–5.570)

0.367

(−)

30

RECIST

SD, PD

10

1.769

(0.705–4.439)

0.225

   

CR, PR

29

Histological evaluation

0, 1a, 1b

17

2.84

(1.152–7.000)

0.023

1.938

(0.612–6.129)

0.260

2, 3

22

CD42b expression

≥10%

24

3.644

(1.213–10.95)

0.021

4.406

(1.325–14.65)

0.016

<10%

15

Podoplanin expression

(+)

28

1.411

(0.512–3.889)

0.505

   

(−)

11

SNAIL expression

(+)

30

1.736

(0.664–4.539)

0.261

   

(−)

9

FOXP3 expression

(+)

7

1.272

(0.369–4.386)

0.703

   

(−)

32

  1. CI confidence interval, CR complete response, ECOG Eastern Cooperative Oncology Group, FOXP3 forkhead box P3, HR hazard ratio, PD progressive disease, PR partial response, RECIST Response Evaluation Criteria in Solid Tumors, SD stable diseases